News

Mycea is gaining recognition in the Ag Biotech ecosystem for its innovative approach to crop protection using forest fungi extracts. Les Échos Coverage – December 1, 2025 “Mycea uses mushroom extracts to protect crops from diseases”  Les Échos, France’s leading business newspaper, features Mycea’s mission to develop natural biocontrol solutions from forest fungi. The article explores our scientific approach, our lead candidate approaching regulatory phases, and our upcoming fundraising round.  About Our Innovation  Mycea has built a proprietary collection of over 750 wild forest fungal species, systematically explored for their potential in crop disease control. After seven years of rigorous lab and field testing, we’ve identified a lead extract candidate with exceptional efficacy against multiple crop diseases at very low doses. This extract is produced in bioreactors where our team has optimized both the cultivation process and extraction methods to ensure industrial-scale viability at competitive pricing.  Why Now  As Europe progressively withdraws toxic chemical fungicides from the market, farmers urgently need effective, safe alternatives. Mycea’s natural solutions address this critical gap while meeting the economic and agronomic requirements of a more resilient agriculture.  Leadership  Mycea is co-led by:  – Dominique Barry-Etienne, co-founder and CEO Science & Technology (founded 2018)  – Aline Bsaibes, CEO Business & Partnerships (former CEO of ITK, French Agtech pioneer)  “We are looking for a combination of three criteria: effectiveness against a wide range of diseases, non-toxicity, and the ability to produce at scale with competitive pricing,” explains Aline Bsaibes in the article.  Next Steps  Mycea is preparing a new funding round to advance its lead candidate through regulatory approval in Europe and South America, with a goal to bring effective biocontrol solutions to farmers through industrial partnerships. Read the article in Les Échos

In its January 7th edition, the business monthly La Lettre M highlights our development strategy and the creation of a spin-off dedicated to commercializing soil biodiversity regeneration solutions. After 5 years of R&D within MYCEA, the soil biodiversity regeneration activity through amplification of native mycorrhizal fungi from each terroir is giving birth to Amoterra, a company dedicated to its commercialization. This achievement of our strategy is a strong signal of the scalability of our solutions. The ag-biotech company MYCEA is now focused exclusively on its other activity: exploring the biological and biochemical properties of forest fungi for plant health. Key points from the La Lettre M article about MYCEA: Differentiation: MYCEA has 750 tested forest fungal strains and 2,000 active extracts effective against 20+ crop diseases. The two current candidates target diseases severely impacted by a lack of treatment solutions due to active substance bans or resistance development. Industrialization: ARD is MYCEA’s partner for production scale-up. A first 8,000-liter scale-up has already been successfully completed, and a second is underway. Partnerships: “We also want to establish partnerships with industrial players to partner with for commercialization,” says Aline Bsaibes, Business CEO of MYCEA.

MYCEA at CIMA 2025 New biocontrol solutions from forest fungal extracts On December 4th, MYCEA presented its scientific advances at the 14th International Conference on Plant Diseases (CIMA) in Angers. Organized by Végéphyl, this conference brings together researchers, technical institutes, and industry players. The 2025 edition placed plant protection against diseases at the heart of discussions in the context of agroecological transition. A unique extract library and platform approach MYCEA develops biocontrol solutions derived from forest fungi. Our approach is based on a proprietary collection of over 750 forest fungal strains, systematically screened for their potential against crop diseases. “Our method consists of screening, comparing, and prioritizing the most promising extracts according to strict criteria of efficacy, safety, and industrial viability,” explains Dominique Barry-Etienne, Science & Production CEO and co-founder of MYCEA. A rigorous selection process Our development pipeline follows a structured methodology: Each phase integrates toxicological and ecotoxicological assessments aligned with OECD standards, enabling rapid identification of the most promising candidates. Grapevine and potato downy mildew After two years of plant and field trials with Contract Research Organizations (CROs), our lead candidate demonstrates very promising preventive efficacy against grapevine downy mildew (P. viticola) and potato late blight (P. infestans). These results were obtained with documented dose-response data and rigorous comparison against untreated controls and standard references. The solution against downy mildew may already be beneath our feet, in forest ecosystems.